These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8252687)

  • 1. Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B.
    Zhao XQ; Brown BG; Hillger L; Sacco D; Bisson B; Fisher L; Albers JJ
    Circulation; 1993 Dec; 88(6):2744-53. PubMed ID: 8252687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
    Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT
    N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits of lipid-lowering therapy in men with elevated apolipoprotein B are not confined to those with very high low density lipoprotein cholesterol.
    Stewart BF; Brown BG; Zhao XQ; Hillger LA; Sniderman AD; Dowdy A; Fisher LD; Albers JJ
    J Am Coll Cardiol; 1994 Mar; 23(4):899-906. PubMed ID: 8106695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density.
    Zambon A; Hokanson JE; Brown BG; Brunzell JD
    Circulation; 1999 Apr; 99(15):1959-64. PubMed ID: 10208998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy.
    Zambon A; Brown BG; Hokanson JE; Motulsky AG; Brunzell JD
    J Intern Med; 2006 Apr; 259(4):401-9. PubMed ID: 16594908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progression of coronary artery disease predicts clinical coronary events. Long-term follow-up from the Cholesterol Lowering Atherosclerosis Study.
    Azen SP; Mack WJ; Cashin-Hemphill L; LaBree L; Shircore AM; Selzer RH; Blankenhorn DH; Hodis HN
    Circulation; 1996 Jan; 93(1):34-41. PubMed ID: 8616937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.
    Zambon A; Deeb SS; Brown BG; Hokanson JE; Brunzell JD
    Circulation; 2001 Feb; 103(6):792-8. PubMed ID: 11171785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coronary angiographic changes with lovastatin therapy. The Monitored Atherosclerosis Regression Study (MARS).
    Blankenhorn DH; Azen SP; Kramsch DM; Mack WJ; Cashin-Hemphill L; Hodis HN; DeBoer LW; Mahrer PR; Masteller MJ; Vailas LI; Alaupovic P; Hirsch LJ;
    Ann Intern Med; 1993 Nov; 119(10):969-76. PubMed ID: 8214993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regression or reduction in progression of atherosclerosis, and avoidance of coronary events, with lovastatin in patients with or at high risk of cardiovascular disease: a review.
    Frisinghelli A; Mafrici A
    Clin Drug Investig; 2007; 27(9):591-604. PubMed ID: 17705568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serial quantitative coronary angiography and coronary events.
    Mack WJ; Xiang M; Selzer RH; Hodis HN
    Am Heart J; 2000 Jun; 139(6):993-9. PubMed ID: 10827379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of two lipid-lowering treatments on quantitative coronary angiographic endpoints.
    Mack WJ; Xiang M; Shircore AM; Selzer RH; Hodis HN; Azen SP
    Cardiovasc Drugs Ther; 2000 Aug; 14(4):411-8. PubMed ID: 10999648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a).
    Maher VM; Brown BG; Marcovina SM; Hillger LA; Zhao XQ; Albers JJ
    JAMA; 1995 Dec; 274(22):1771-4. PubMed ID: 7500507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events.
    Whitney EJ; Krasuski RA; Personius BE; Michalek JE; Maranian AM; Kolasa MW; Monick E; Brown BG; Gotto AM
    Ann Intern Med; 2005 Jan; 142(2):95-104. PubMed ID: 15657157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease.
    Brown BG; Bardsley J; Poulin D; Hillger LA; Dowdy A; Maher VM; Zhao XQ; Albers JJ; Knopp RH
    Am J Cardiol; 1997 Jul; 80(2):111-5. PubMed ID: 9230143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of niacin, statins, and resins in patients with combined hyperlipidemia.
    Brown BG; Zambon A; Poulin D; Rocha A; Maher VM; Davis JW; Albers JJ; Brunzell JD
    Am J Cardiol; 1998 Feb; 81(4A):52B-59B. PubMed ID: 9526815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination drug therapy for familial combined hyperlipidemia.
    East C; Bilheimer DW; Grundy SM
    Ann Intern Med; 1988 Jul; 109(1):25-32. PubMed ID: 3288029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of lovastatin or niacin combined with colestipol and regression of coronary atherosclerosis.
    Brown BG
    Eur Heart J; 1992 Jul; 13 Suppl B():17-20. PubMed ID: 1644095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study.
    Hodis HN
    J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S25-31. PubMed ID: 8907211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype.
    Artemeva NV; Safarova MS; Ezhov MV; Afanasieva OI; Dmitrieva OA; Pokrovsky SN
    Atheroscler Suppl; 2015 May; 18():53-8. PubMed ID: 25936305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of colestipol-niacin on coronary atherosclerosis. A 4-year follow-up.
    Cashin-Hemphill L; Mack WJ; Pogoda JM; Sanmarco ME; Azen SP; Blankenhorn DH
    JAMA; 1990 Dec; 264(23):3013-7. PubMed ID: 2243429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.